ArticleClinical cardiology2024

Cost-Effectiveness and Budget Impact Analysis of Apixaban and Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Non-Valvular Atrial Fibrillation (NVAF) in Iran.

Amirmohammad Tajik et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.